drugset

drugset / Trial / NCT00502164

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

NCT00502164 ↗

Phase 1 Completed 40 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

Timeline

Start: 2004-03
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cediranib	Small molecule	—	Oral

Indications